Low-dose Colchicine for CABG Graft Failure Prevention
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeijing Anzhen Hospital
About this trial
This study aims to evaluate whether daily low-dose colchicine (0.5 mg), administered in addition to the standard secondary prevention regimen recommended in clinical guidelines after coronary artery bypass grafting (CABG), can further prevent graft failure after CABG through a prospective, randomized, double-blind, placebo-controlled clinical trial.
Eligibility criteria
Qualifiers
Be male or female, aged 18 years or older;
Within 3 days after successful isolated coronary artery bypass grafting (CABG);
Sign informed consent;
Disqualifiers
Severe valvular heart disease requiring concomitant or staged valvular surgery;
History of non-skin cancer in the past 3 years;
Inflammatory bowel disease or chronic diarrhea;
Neuromuscular diseases or non-transient creatine kinase levels greater than 3 times the upper limit of the normal range (except those associated with myocardial infarction);
Trial design
Treatments tested in this trial
- Colchicine Pill
- Placebo
Treatment groups
622 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov